Cyclacel Pharmaceuticals Changes Principal Executive Offices
Ticker: BGMSP · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1130166
Sentiment: neutral
Topics: corporate-action, relocation
Related Tickers: CYCC
TL;DR
Cyclacel Pharmaceuticals moved its HQ to Malaysia. Big changes brewing?
AI Summary
On April 21, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to Kuala Lumpur, Malaysia. This move follows a period where the company was formerly known as Xcyte Therapies Inc. before a name change on December 18, 2000.
Why It Matters
A change in principal executive offices can signal shifts in operational focus, management structure, or strategic direction for the company.
Risk Assessment
Risk Level: medium — Relocation of principal executive offices can indicate significant operational or strategic shifts, which carry inherent risks.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- 20001218 (date) — Date of name change
- April 21, 2025 (date) — Date of report
- Kuala Lumpur, Malaysia (location) — New principal executive offices
FAQ
What is the new address of Cyclacel Pharmaceuticals' principal executive offices?
The new address is Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia 592000.
When was the report filed?
The report was filed on April 21, 2025.
What was Cyclacel Pharmaceuticals formerly known as?
The company was formerly known as XCYTE THERAPIES INC.
When did the company change its name from XCYTE THERAPIES INC?
The date of the name change was December 18, 2000.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).